Tamarind Bio

tamarind.bio →

+41%

est. 2Y upside i

HealthcareAI & MLSeries A

AI Inference Platform for Drug Discovery

Rank

#80

Sector

Biotechnology, AI, SaaS

Est. Liquidity

~4Y

Data Quality

Data: Medium

Tamarind Bio presents a strong upside opportunity driven by its exceptional 700% YoY growth and cash-flow positive status, which is rare for a Series A company.

Last updated: March 10, 2026

Bull (35%)+350%

Tamarind Bio expands its platform to become the dominant operating system for AI in drug discovery, launching new advanced model orchestration features and expanding into adjacent R&D workflows. This drives revenue to over $100M by 2028, justifying a valuation of $787.5M (4.5x current) as a market leader.

Base (40%)+150%

Tamarind Bio continues its strong growth, solidifying its position as a key infrastructure provider for AI in drug discovery. It expands its customer base and deepens integrations, reaching approximately $50M in ARR by 2028 and achieving an acquisition valuation of $437.5M (2.5x current).

Bear (25%)-75%

Increased competition from large cloud providers offering specialized AI/ML tools and large pharmaceutical companies developing robust in-house platforms slows Tamarind Bio's customer acquisition and growth. Revenue growth stalls, leading to a down round or acquisition at a significantly reduced valuation of $43.75M, wiping out most common stock value.

Est. time to liquidity~3.5 years

Preference Stack Risk

moderate

Investors hold $14.1M in liquidation preferences ahead of common stock. In an exit at or below $14.1M, common stock would receive little to nothing.

Dilution Risk

moderate

As a Series A company, Tamarind Bio will likely raise additional funding rounds (Series B, C, etc.) before a liquidity event, which will dilute existing equity holders.

Secondary Liquidity

none

There are no active secondary markets or tender offers for a company at this early stage.

Engineering — 2 roles

Science — 1 role

View all 3 open roles at Tamarind Bio →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Tamarind Bio's data — designed to show you've done your homework.

  • 1

    “Given the stated 700% YoY growth and cash-flow positive status, how does Tamarind Bio plan to maintain this rapid growth trajectory and profitability as it scales, especially with potential increased competition from large pharmaceutical companies building in-house solutions or larger tech players entering the specialized AI infrastructure space?”

  • 2

    “With 8 of the top 20 pharma companies as customers and 10,000+ scientists using the platform, what are the key strategies for expanding revenue per customer and penetrating deeper into the broader TAM, beyond the current core offerings?”

  • 3

    “As a Series A company, what is the anticipated timeline for future funding rounds and potential liquidity events (e.g., IPO or acquisition), and how does the company plan to manage employee equity dilution through these stages?”

Community

Valuation Sentiment

Our model estimates +41% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.